Your browser is no longer supported. Please, upgrade your browser.
Settings
FATE Fate Therapeutics, Inc. daily Stock Chart
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own1.78% Shs Outstand66.60M Perf Week-5.87%
Market Cap1.07B Forward P/E- EPS next Y-1.16 Insider Trans254.91% Shs Float63.37M Perf Month15.56%
Income-63.10M PEG- EPS next Q-0.24 Inst Own88.80% Short Float12.65% Perf Quarter10.70%
Sales4.10M P/S260.55 EPS this Y2.90% Inst Trans-1.00% Short Ratio9.47 Perf Half Y44.77%
Book/sh3.21 P/B5.00 EPS next Y3.30% ROA-50.30% Target Price18.43 Perf Year123.40%
Cash/sh3.17 P/C5.06 EPS next 5Y- ROE-68.60% 52W Range6.76 - 17.98 Perf YTD25.02%
Dividend- P/FCF- EPS past 5Y-6.60% ROI-45.90% 52W High-10.79% Beta2.19
Dividend %- Quick Ratio9.40 Sales past 5Y9.00% Gross Margin- 52W Low137.28% ATR1.20
Employees80 Current Ratio9.40 Sales Q/Q0.00% Oper. Margin- RSI (14)56.64 Volatility5.54% 9.12%
OptionableYes Debt/Eq0.09 EPS Q/Q-20.10% Profit Margin- Rel Volume0.88 Prev Close16.57
ShortableYes LT Debt/Eq0.07 EarningsJan 31 AMC Payout- Avg Volume846.77K Price16.04
Recom1.80 SMA2010.32% SMA5011.00% SMA20028.19% Volume749,313 Change-3.20%
Jan-03-19Downgrade Stephens Overweight → Equal-Weight
Nov-05-18Initiated Jefferies Buy
Aug-01-18Initiated Citigroup Buy $20
Mar-06-18Downgrade H.C. Wainwright Buy → Neutral $12
Dec-18-17Initiated Piper Jaffray Overweight $10
Oct-12-17Resumed H.C. Wainwright Buy $7
Sep-08-17Resumed Leerink Partners Outperform $7
Nov-08-16Reiterated Wedbush Outperform $8 → $7
Sep-22-16Initiated ROTH Capital Buy $8
Jul-28-16Resumed H.C. Wainwright Buy $9
Dec-04-15Initiated Wells Fargo Outperform
Oct-06-15Initiated Raymond James Outperform $8
Jun-01-15Initiated Leerink Partners Outperform $10
May-11-15Reiterated H.C. Wainwright Buy $9 → $11
Sep-08-14Initiated H.C. Wainwright Buy $9
Oct-28-13Initiated Cowen Outperform
Dec-19-18 12:04AM  Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up Insider Monkey -6.05%
Dec-04-18 09:11AM  Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting GlobeNewswire
Dec-03-18 04:01PM  Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products GlobeNewswire +10.48%
08:44AM  Fate Therapeutics (FATE) Jumps: Stock Rises 8.9% Zacks
07:40AM  Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 09:30AM  How Healthcare Is Evolving & Sector Stocks To Watch ACCESSWIRE +8.94%
09:10AM  Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment MarketWatch
08:00AM  Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy GlobeNewswire
Nov-28-18 04:22PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
Nov-16-18 10:35AM  What Kind Of Shareholder Appears On The Fate Therapeutics Incs (NASDAQ:FATE) Shareholder Register? Simply Wall St.
Nov-11-18 05:42PM  Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 GlobeNewswire
Nov-08-18 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -10.00%
Nov-07-18 01:15AM  Edited Transcript of FATE earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 06:40PM  Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates Zacks +9.23%
05:35PM  Fate Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
09:01AM  Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting GlobeNewswire
Oct-29-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results GlobeNewswire -7.30%
Oct-25-18 03:55PM  3 Healthcare Stocks To Watch On Thursday ACCESSWIRE +17.68%
Oct-24-18 09:10AM  New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -9.89%
Oct-04-18 08:00AM  Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations GlobeNewswire
Oct-03-18 07:00AM  This Biotech Stock Has Quadrupled and Its Top Shareholder Is Still Buying Barrons.com
Sep-25-18 04:01PM  Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
08:00AM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-20-18 11:37PM  Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +5.01%
04:11PM  Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
01:32PM  Why You Need To Look At This Factor Before Buying Fate Therapeutics Inc (NASDAQ:FATE) Simply Wall St.
Sep-17-18 07:00PM  Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies GlobeNewswire
Sep-13-18 08:00AM  Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming GlobeNewswire
Sep-11-18 02:12PM  Edited Transcript of FATE earnings conference call or presentation 6-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-31-18 08:10AM  Research Report Identifies Kronos Worldwide, The Gap, Citigroup, Cadence Design, SPX FLOW, and Fate Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-07-18 04:01PM  Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire +11.21%
Aug-06-18 06:00PM  Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:58PM  Fate Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
03:00PM  Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:39AM  Fate Therapeutics Q2 Earnings Preview Benzinga
Jul-30-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2018 Financial Results GlobeNewswire
Jul-27-18 07:35AM  Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-26-18 10:59AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Fate Therapeutics, Inc. -- FATE GlobeNewswire
06:57AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Fate Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
Jun-21-18 09:48AM  3 Sectors to Buy in a Trade War Investopedia
Jun-01-18 04:01PM  Fate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 07:40AM  Analysis: Positioning to Benefit within Beazer Homes, Tejon Ranch, Ladder Capital, Fate Therapeutics, Benefitfocus, and H&E Equipment Services Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-16-18 08:00AM  Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies GlobeNewswire +5.06%
May-10-18 11:46PM  Edited Transcript of FATE earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
04:07PM  Fate Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
May-03-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results GlobeNewswire
May-02-18 08:00AM  Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-16-18 09:30AM  Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program GlobeNewswire
Apr-10-18 03:03PM  Fate Therapeutics Incs (NASDAQ:FATE) Shift From Loss To Profit Simply Wall St. +6.12%
Apr-03-18 07:05AM  Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100's APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018 ACCESSWIRE
Mar-30-18 01:31PM  Edited Transcript of FATE earnings conference call or presentation 1-Nov-17 9:00pm GMT Thomson Reuters StreetEvents
Mar-29-18 08:00AM  Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 GlobeNewswire
Mar-28-18 07:45AM  Recent Analysis Shows EPAM, Sibanye Gold, Fate Therapeutics, Howard Hughes, CBL & Associates Properties, and Quorum Health Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -6.84%
Mar-27-18 10:43AM  Edited Transcript of FATE earnings conference call or presentation 5-Mar-18 10:00pm GMT Thomson Reuters StreetEvents -11.50%
Mar-19-18 08:00AM  Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune GlobeNewswire
Mar-13-18 07:40AM  Wired News CTI BioPharmas Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology ACCESSWIRE -7.58%
Mar-05-18 04:15PM  Fate Therapeutics reports 4Q loss Associated Press
04:01PM  Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress GlobeNewswire
Feb-27-18 08:00AM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-24-18 10:37AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-23-18 08:00AM  Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy GlobeNewswire +11.15%
Feb-20-18 08:00AM  Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors GlobeNewswire
Feb-12-18 04:01PM  Fate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-05-18 03:49PM  With A -16.46% Earnings Drop, Is Fate Therapeutics Incs (NASDAQ:FATE) Performance A Concern? Simply Wall St. -9.71%
Jan-25-18 08:25AM  Research Report Identifies Fate Therapeutics, A. Schulman, Celadon Group, Egalet, Meredith, and HCP with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-23-18 12:09PM  Here's Why Fate Therapeutics Rose as Much as 18% Today Motley Fool +10.01%
Jan-18-18 06:27PM  3 Stocks Under $10 That Surged Today Zacks
Dec-30-17 10:37AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Dec-28-17 08:38AM  Fate Therapeutics (FATE) Jumps: Stock Rises 5.7% Zacks -8.28%
Dec-21-17 11:26AM  ETFs with exposure to Fate Therapeutics, Inc. : December 21, 2017 Capital Cube +12.42%
Dec-15-17 04:01PM  Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-13-17 08:00AM  Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-12-17 04:01PM  Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +7.13%
Dec-11-17 06:13PM  Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune and Initiation of Phase 2 Stage GlobeNewswire
04:30PM  Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 GlobeNewswire
Dec-09-17 12:30PM  Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy GlobeNewswire
Dec-08-17 04:01PM  Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer GlobeNewswire
Dec-06-17 08:00AM  Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies GlobeNewswire
Dec-05-17 09:00AM  Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock? Zacks
Nov-21-17 08:00AM  Fate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference GlobeNewswire
Nov-17-17 11:52AM  ETFs with exposure to Fate Therapeutics, Inc. : November 17, 2017 Capital Cube
Nov-16-17 10:23AM  Boston Children's reverses type 1 diabetes in mice American City Business Journals +8.27%
Nov-10-17 08:00AM  Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting GlobeNewswire
Nov-06-17 11:34AM  ETFs with exposure to Fate Therapeutics, Inc. : November 6, 2017 Capital Cube
Nov-03-17 10:07AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-01-17 05:30PM  Fate Therapeutics reports 3Q loss Associated Press
04:01PM  Fate Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
01:00PM  Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
09:00AM  Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting GlobeNewswire
Oct-25-17 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results GlobeNewswire
Oct-16-17 09:52AM  ETFs with exposure to Fate Therapeutics, Inc. : October 16, 2017 Capital Cube
Oct-12-17 03:32PM  4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate Benzinga
Oct-05-17 11:00AM  ETFs with exposure to Fate Therapeutics, Inc. : October 5, 2017 Capital Cube
Oct-04-17 09:09AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 Capital Cube
Sep-18-17 08:00AM  Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune for Prevention of Acute Graft-versus-Host Disease GlobeNewswire
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells; and a collaboration agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TAHL CINDYGeneral Counsel and SecretaryJan 07Option Exercise2.2725,00056,67370,418Jan 09 04:03 PM
TAHL CINDYGeneral Counsel and SecretaryJan 07Sale16.0025,000400,00045,418Jan 09 04:03 PM
Nashat AmirDirectorDec 20Sale12.2533,474410,1601,823,186Dec 26 04:13 PM
Nashat AmirDirectorDec 19Sale13.4091,2101,222,5921,856,660Dec 21 04:12 PM
Nashat AmirDirectorDec 13Sale16.6717,788296,5631,947,870Dec 17 04:25 PM
Nashat AmirDirectorDec 12Sale16.78425,0007,132,6901,965,658Dec 14 04:33 PM
Nashat AmirDirectorDec 11Sale16.7182,5281,379,1832,390,658Dec 13 05:14 PM
Redmile Group, LLCDirectorSep 25Buy13.503,703,70450,000,00410,359,666Sep 27 04:23 PM
ABBOT STEWARTChief Development OfficerMay 15Option Exercise6.6221,054139,41164,917May 16 05:28 PM